SCHEMBL26212922

SCHEMBL26212922

CC(C)Oc1ccc(S(=O)(=O)NCCCl)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.51
PKM P14618 1/20 0.51
FFAR4 Q5NUL3 1/20 0.51
TP53 P04637 2/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
MMP1 P03956 1/20 0.46
MMP2 P08253 1/20 0.46
MMP3 P08254 1/20 0.46
MMP7 P09237 1/20 0.46
MMP9 P14780 1/20 0.46
MMP8 P22894 1/20 0.46
MMP13 P45452 1/20 0.46
MMP14 P50281 1/20 0.46
POLB P06746 1/20 0.44
KDM4E B2RXH2 1/20 0.44
NPC1 O15118 1/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20314698 0.83 ALDH1A1 (0.58) ALDH1A1PKMFFAR4TP53SMN1; SMN2
SCHEMBL12499028 0.82 ALDH1A1 (0.75) ALDH1A1PKMSMN1; SMN2MMP1MMP2
SCHEMBL29306670 0.80 ALDH1A1 (0.57) ALDH1A1PKMFFAR4TP53SMN1; SMN2
SCHEMBL26212905 0.79 ALDH1A1 (0.53) ALDH1A1PKMSMN1; SMN2KDM4ELMNA
SCHEMBL25431630 0.78 FFAR4 (0.51) ALDH1A1PKMFFAR4TP53SMN1; SMN2
SCHEMBL1504601 0.76 ALDH1A1 (0.66) ALDH1A1SMN1; SMN2LMNAHPGDMEN1
SCHEMBL9978287 0.76 SMN1; SMN2 (0.66) ALDH1A1FFAR4TP53SMN1; SMN2MMP1
SCHEMBL26212929 0.76 MMP2 (0.63) ALDH1A1PKMFFAR4SMN1; SMN2MMP1
SCHEMBL26212911 0.76 L3MBTL1 (0.56) ALDH1A1PKMFFAR4SMN1; SMN2MMP1
SCHEMBL26212925 0.76 ALDH1A1 (0.47) ALDH1A1PKMSMN1; SMN2KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115843271-B Indole derivatives and their use for the treatment of cancer 克洛德贝纳尔-里昂第一大学 2024-08-13 CN disclosed
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2023-09-07 US disclosed
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2023-09-07 US disclosed
CN-115843271-A Indole derivatives and their use for the treatment of cancer 克洛德贝纳尔-里昂第一大学 2023-03-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER CSNK2A1, IDO1, CSNK2A3 ALDH1A1 995/4885PKM 502/4885FFAR4 4564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.